| Zacks Company Profile for Liquidia Technologies, Inc. (LQDA : NSDQ) |
|
|
| |
| • Company Description |
| Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
Number of Employees: 170 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $14.60 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,975,085 shares |
| Shares Outstanding: 85.49 (millions) |
| Market Capitalization: $1,248.07 (millions) |
| Beta: -0.01 |
| 52 Week High: $19.41 |
| 52 Week Low: $8.26 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
7.04% |
1.66% |
| 12 Week |
4.06% |
-9.37% |
| Year To Date |
24.15% |
15.95% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Roger A. Jeffs - Chief Executive Officer and Director
Stephen Bloch - Chairman of the Board of Directors
Michael Kaseta - Chief Operating Officer and Chief Financial Office
Damian deGoa - Director
Katherine Rielly-Gauvin - Director
|
|
Peer Information
Liquidia Technologies, Inc. (CORR.)
Liquidia Technologies, Inc. (RSPI)
Liquidia Technologies, Inc. (CGXP)
Liquidia Technologies, Inc. (BGEN)
Liquidia Technologies, Inc. (GTBP)
Liquidia Technologies, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 53635D202
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 85.49
Most Recent Split Date: (:1)
Beta: -0.01
Market Capitalization: $1,248.07 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.35 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.58 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
